Business context and reporting period
Ligand Pharmaceuticals Incorporated’s Form 10-K covers the fiscal year ended December 31, 2012; the filing also reports unaudited fourth-quarter results. Ligand’s asset-light biotechnology model centers on licensing drug candidates and Captisol formulation technology to partners, generating royalties, milestones, license fees and Captisol sales. Its portfolio included more than 80 potential revenue-generating programs, over 70 partner-funded programs, and six FDA-approved products using Captisol.
Financial performance and position
| Metric | 2012 | 2011 |
|---|---|---|
| Total revenue | $31.4 million | $30.0 million |
| Royalties | $14.1 million | $9.2 million |
| Captisol material sales | $9.4 million | $12.1 million |
| Collaborative R&D and other revenue | $7.9 million | $8.7 million |
| Operating income (loss) | $0.6 million | $(0.7) million |
| Income (loss) from continuing operations | $(2.7) million | $9.7 million |
| Net income (loss) | $(0.5) million | $9.7 million |
| Operating cash flow, consolidated | $0.2 million provided | $1.2 million used |
Royalty growth reflected increased Promacta sales. Lower material sales were attributed to the timing of Captisol customer purchases. Continuing-operations R&D expense was $10.8 million, versus $10.3 million; Ligand funded 100% of 2012 R&D expense. General and administrative expense was $16.1 million, compared with $15.0 million. Operating income was approximately 1.8% of revenue; the filing does not present a company-wide gross-margin figure.
Full-year results included a $1.2 million continuing-operations tax benefit, $3.3 million net interest expense and a $1.7 million increase in contingent liabilities. The prior-year $9.7 million continuing-operations profit included a $13.3 million tax benefit, principally from deferred tax liabilities recorded in the CyDex acquisition. In 2012, a $3.7 million pre-tax gain from the previously sold Avinza product line contributed to discontinued-operations income; this was partly offset by $1.5 million of related tax expense. Fourth-quarter revenue was $13.6 million; continuing-operations income was $2.6 million and net income was $1.1 million.
At year-end, cash and cash equivalents were $12.4 million, short-term investments were zero, and restricted cash and investments were $2.8 million. Working capital was negative $11.6 million; accumulated deficit was $682.8 million. Term-loan principal was $27.5 million, at fixed rates of 8.6% and 8.9%, due August 2014; the company had no balance on its cash-collateralized revolving line. Current and long-term note-payable carrying amounts were $14.8 million and $13.4 million, respectively. Total assets were $104.3 million and stockholders’ equity was $26.5 million.
Changes, outlook, risks and unusual items
- Revenue increased 4.5% year over year, with royalties up about 53%; lower Captisol sales and collaborative revenue partly offset the increase. The company reported an operating profit but a continuing-operations loss, while 2011’s reported profit was strongly affected by its tax benefit.
- Management said available resources and expected royalty, license and milestone receipts should fund operations at current levels for at least 12 months. It cited anticipated growth in Captisol sales and royalties, particularly from Promacta and Kyprolis, and said discretionary spending could be reduced if cash generation fell short. No formal revenue or earnings guidance was provided.
- Promacta received FDA approval in November 2012 for thrombocytopenia in chronic hepatitis C patients receiving interferon-based therapy. Kyprolis received accelerated FDA approval in July 2012; Ligand received a $0.6 million milestone and is eligible for tiered royalties. Merck initiated a Phase II/III dinaciclib trial, triggering a $2 million milestone.
- Subsequent to year-end, Ligand reported a $1.4 million Retrophin milestone receipt and a March 2013 Spectrum license for Captisol-enabled melphalan, including a $3 million fee, potential milestones exceeding $50 million and double-digit royalties if commercialized. These are post-year-end developments, not 2012 revenue.
- Liquidity and execution risks include dependence on partner decisions and product sales, negative working capital, debt payments beginning after the interest-only period, and reliance on a sole Captisol supplier, Hovione. Ligand reported inventory expected to support existing supply obligations through 2013 under anticipated demand, but warned unusual orders or supply disruption could impair operations.
- The auditor gave an unqualified opinion on the financial statements but an adverse opinion on internal control over financial reporting. Material weaknesses involved accounting for non-routine transactions and valuation of contingent liabilities; the filing says prior interim and annual reports were restated. Management added a controller and described planned remediation, which was not yet complete.
- A securities class action and derivative suit relating to a 2010 licensing-interest purchase named Ligand and its CEO; the company said it would defend the claims and that the outcome was not determinable. A separate Chiva dispute was settled in October 2012: Chiva paid $0.1 million, and Ligand relinquished its asserted $1.7 million claim and recovered the Fablyn rights.
Important facts for investors to verify
- Track Promacta and Kyprolis sales, Ligand’s product-specific royalty receipts, and the concentration of revenue among partners and customers.
- Review cash generation, the negative working-capital position, term-loan amortization and maturity, and any need for additional financing or equity issuance.
- Assess Captisol supply continuity, Hovione capacity and qualification of alternative sources, alongside demand and inventory levels.
- Check progress and evidence of remediation of internal-control material weaknesses, and review any subsequent restatements or reporting changes.
- Monitor clinical, regulatory and commercialization progress across partnered programs, plus resolution of the securities litigation and any remaining contingent obligations.